Clinical results of cervix cancer treatment using various technologies in radiation therapy

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: The study reported clinical results of patients with cervical cancer, who were treated with different methodological approaches of radiation therapy (RT), switching from conventional to conformal irradiation, as well as different brachytherapy (BT) techniques.

AIM: To evaluate long-term results of treatment, locoregional and distant control.

METHODS: 137 patients having stage IIB–IIIB cervical cancer in 2013–2016 were analyzed retrospectively. 70 patients (51%), divided in two groups of n=35, were treated with conventional RT and two-dimensional (2D) planning of intracavitary BT with 60Сo alone or in combination with cisplatin (40 mg/m2). The total dose (TD) for point A was 75.08±0.57 Gy, for point B — 57.9±0.43 Gy. 67 patients (49%), divided in two groups of n=35 and n=32, were treated with conformal external-beam RT following three-dimensional (3D) planning of intracavitary BT with 192Ir alone or in combination with cisplatin (40 mg/m2), respectively. Total D90 of high-risk clinical target volume was 95.0±0.67 Gy EQD2 (Equivalent Total Dose in 2 Gy fraction).

RESULTS: 3- and 5-year overall survival rate with 3D-RT versus 2D-RT was 84.6±4.5% vs 63.1±6.0% and 84.6±4.5% vs 56.1±6.0%, respectively (p=0.030). It was revealed that modern technologies are also important in improving overall survival with image-guided RT: 3-year overall survival rate was higher in the group of image-guided RT combined with 3D-BT — 88.2±6.6% versus 59.0±8.4%, respectively (p=0.027). The use of chemoradiotherapy showed an advantage for 3-year event-free survival in groups with 2D RT — 67.9±8.4% versus 55.2±8.6% (p=0.042). Between the groups where 3D RT was used, no statistically significant differences were recorded. Locoregional control was higher in the 3D RT groups at 3 years of follow-up: 97.0±2.9% versus 82.9±5.3%, p=0.050. Chemoradiotherapy allows to reduce the number of local failures in the pelvis in the follow-up period up to 6 months, regardless of the RT technologies. The number of relapses and metastases in pelvis is lower when using 3D RT (3.0±2.1%) compared with 2D (15.7±4.4%), p=0.05. There was no statistically significant difference in the frequency of detection of metastases: with 2D RT — 5.7±2.8%, and with 3D RT — 9.0±3.5% (p >0.05).

CONCLUSIONS: The study proves the improvement of local control when using conformal RT and 3D-BT, which is an important component in the RT program for cervical cancer.

作者简介

Olga Kravets

JSC «Medicine»; The Russian National Research Medical University named after N.I. Pirogov

Email: Kravetz_olga@mail.ru
ORCID iD: 0000-0002-3347-5278
SPIN 代码: 8311-0979
Scopus 作者 ID: 6506974295

MD, Dr. Sci. (Med.), Assistant Professor

俄罗斯联邦, 10 2nd Tverskoy-Yamskoy Pereulok, 125047 Moscow; 1, Moskvorechye str., 115578 Moscow

Anara Kurmanova

Kazakh Institute of Oncology and Radiology

Email: anara_kurmanova@mail.ru
ORCID iD: 0009-0009-6568-1402
SPIN 代码: 6872-8278
Scopus 作者 ID: Anara24101977

MD

哈萨克斯坦, Almaty

Vladimir Bogatyrev

N.N. Blokhin National Medical Research Center of Oncology

编辑信件的主要联系方式.
Email: bogatyrevvn@mail.ru
ORCID iD: 0000-0003-3713-9770
SPIN 代码: 8493-8443

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

参考

  1. Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 godu. Moscow: MNIOI im. P.A. Gertsena — NMRRC of the Ministry of Health of Russia branch; 2022. (In Russ).
  2. Romanova EA, Kravets OA, Nechushkin MI. Sovremennye metodiki luchevoi terapii v lechenii mestnorasprostranennogo raka sheiki matki. Vestnik RONTs im. N.N. Blokhina RAMN. 2017;28(3-4):26–31. (In Russ).
  3. Pötter R, Georg P, Dimopoulos JC, et al. Clinical outcome of protocol-based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiotherapy Oncology. 2011;100(1):116-123. doi: 10.1016/j.radonc.2011.07.012
  4. Lin AJ, Kidd E, Dehdashti F, et al. Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. International Journal of Radiation Oncology*Biology*Physics. 2019;103(5):1088–1097. doi: 10.1016/j.ijrobp.2018.11.012
  5. Mayadev J, Viswanathan A, Liu Y, et al. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate Brachytherapy for cervical cancer. Brachytherapy. 2017;16(1):22–43. doi: 10.1016/j.brachy.2016.03.008
  6. Kravets OA, Romanova EA, Gorbunova VA. Clinical results of radiation and chemoradiation therapy of locally advanced cervix cancer. Russian Journal of Oncology. 2020;25(3):92–102. (In Russ). doi: 10.17816/1028–9984–2020-25-3-92-102
  7. Gill BS, Kim H, Houser CJ, et al. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. International Journal of Radiation Oncology*Biology*Physics. 2015;91(3):540–547. doi: 10.1016/j.ijrobp.2014.10.053
  8. Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiotherapy and Oncology. 2007;83(2):148–155. doi: 10.1016/j.radonc.2007.04.012
  9. Mahantshetty U, Krishnatry R, Hande V, et al. Magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer: an experience from a tertiary cancer center in a low and middle-income countries setting. International Journal of Radiation Oncology*Biology*Physics. 2017;99(3):608–617. doi: 10.1016/j.ijrobp.2017.06.010
  10. Ohno T, Noda SE, Okonogi N, et al. In-room computed tomography-based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study. Journal of Radiation Research. 2017;58(4):543–551. doi: 10.1093/jrr/rrw121
  11. Narayan K, van Dyk S, Bernshaw D, et al. Ultrasound guided conformal brachytherapy of cervix cancer: Survival, patterns of failure, and late complications. Journal of Gynecologic Oncology. 2014;25(3):206–213. doi: 10.3802/jgo.2014.25.3.206
  12. Möller S, Mordhorst LB, Hermansson RS, et al. Combined external pelvic chemoradiotherapy and image-guided adaptive brachytherapy in treatment of advanced cervical carcinoma: experience from a single institution. Journal of Contemporary Brachytherapy. 2020;12(4):356–366. doi: 10.5114/jcb.2020.98116
  13. Kravets OA, Andreeva YuV, Kozlov OV, Nechushkin MI. Modern aspects of clinical and radiobiological brachytherapy planning of advanced cervix cancer. Meditsinskaya Fizika (Medical Physics). 2009;(2):10–17. (In Russ).
  14. Kravets OA, Romanova EA, Kozlov OV, et al. Three-dimensional planning of brachytherapy for locally advanced cervical cancer by CT/MRI images. Voprosy Onkologii (Problems in Oncology). 2018;64(5):645–650. (In Russ). doi: 10.37469/0507-3758-2018-64-5
  15. Kravets OA, Kozlov OV, Fedyanina AA, Kuznetsov MA, Nechushkin MI. Cervix cancer 3D brachytherapy methodic aspects. Meditsinskaya Fizika (Medical Physics). 2017;(1):16–24. (In Russ).
  16. Hsieh CH, Tsai SJ, Chiou WY, et al. Better survival with three-dimensional conformal radiotherapy than with conventional radiotherapy for cervical cancer: a population-based study. International Scholarly Research Notices. 2013;2013:729–819. doi: 10.1155/2013/729819
  17. Goswami J, Patra NB, Sarkar B, et al. Dosimetric comparison between conventional and conformal radiotherapy for carcinoma cervix: Are we treating the right volumes? South Asian Journal of Cancer. 2013;2(3):345–349. doi: 10.4103/2278-330x.114112
  18. Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE- I): a multicenter prospective cohort study. The Lancet Oncology. 2021;22(4):538–547. doi: 10.1016/S1470-2045(20)30753-1
  19. Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiotherapy and Oncology. 2016;120(3):428–433. doi: 10.1016/j.radonc.2016.03.011
  20. Castelnau-Marchand P, Chargari C, Maroun P, et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecologic Oncology. 2015;139(2):288–294. doi: 10.1016/j.ygyno.2015.09.008
  21. Lindegaard JC, Fokdal LU, Nielsen SK, et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncologica. 2013;52(7):1510–1519. doi: 10.3109/0284186x.2013.818253
  22. Ribeiro I, Janssen H, De Brabandere M, et al. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients. Radiotherapy and Oncology. 2016;120(3):447–454. doi: 10.1016/j.radonc.2016.04.016

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig 1. Distribution of the total number of patients with cervical cancer by stages (n=137), %.

下载 (40KB)
索引源数据
3. Fig. 2. Distribution of patients with cervical cancer by stages in groups, %.

下载 (101KB)
索引源数据
4. Fig. 3. Locoregional control in groups depending on radiotherapy technologies, p=0.05, %.

下载 (62KB)
索引源数据
5. Fig. 4. Progression of cervical cancer in groups in terms of 2 to 6 months of follow-up after radio/chemoradiotherapy, %.

下载 (64KB)
索引源数据
6. Fig. 5. Analysis of pelvis relapses and metastases in groups, taking into account the applied radiation therapy technologies in patients with cervical cancer, p=0.05, %.

下载 (46KB)
索引源数据
7. Fig. 6. Analysis of distant metastases frequency in groups, concerning the applied radiation therapy technologies in patients with cervical cancer, p > 0.05, %.

下载 (45KB)
索引源数据

版权所有 © Eco-Vector, 2022


 


##common.cookie##